A Study of GEN1106 in Participants With Solid Tumors
Phase 1
18+
3 sites in NY, SC, TX
What this study is about
This Phase 1 study is focused on people with solid tumors. The primary outcome being measured is Part 1 Dose Escalation: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Part 1 Dose Escalation: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Part 2 Dose Refinement: Number of Participants with AEs and SAEs, Part 3 Expansion: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Secondary: Part 1 Dose Escalation and Part 2 Dose Refinement: Disease Control Rate (DCR) per RECIST v1.1, Part 1 Dose Escalation and Part 2 Dose Refinement: Duration of Response (DOR) per RECIST v1.1, Part 1 Dose Escalation and Part 2 Dose Refinement: ORR per RECIST v1.1, Part 3 Expansion: DCR per RECIST v1.1, Part 3 Expansion: DOR per RECIST v1.1, Part 3 Expansion: Number of Participants with AEs and SAEs
Oncology